Assessment of the in vitro and in vivo genotoxicity of Thalomid (thalidomide)
- PMID: 10992277
- DOI: 10.1002/1520-6866(2000)20:5<301::aid-tcm6>3.0.co;2-2
Assessment of the in vitro and in vivo genotoxicity of Thalomid (thalidomide)
Abstract
Thalomid is the FDA-approved commercial formulation of thalidomide currently used in the US to treat erythema nodosum leprosum, a complication of leprosy. The genotoxicity of Thalomid thalidomide was assessed in the Ames reverse mutation, AS52/XPRT mammalian cell forward gene mutation, and mouse bone marrow micronucleus assays. The Ames and AS52 assays were performed with and without S9. In the Ames, Salmonella typhimurium strains TA1535, 1537, 98, 100, and 102 and Escherichia coli strain WP2 uvrA were used. Assays were performed by using plate incorporation and liquid pre-incubation systems at thalidomide doses of 50-10,000 microg/plate. In the AS52 assay, Chinese hamster ovary cells were plated with fortified Ham's F12 medium and incubated overnight. The medium was then incubated with 1-1000 microg/ml thalidomide. After a series of aspirations, washings, reconstitutions, and incubations, mutant AS52 cells were fixed and stained. Colonies were then counted and the relative survival frequencies compared to negative controls. In the mouse micronucleus assay, Crl:CD-1 albino mice were dosed with 500, 2,500, and 5,000 mg/kg thalidomide and sacrificed over 72 h. Femurs were flushed with fetal bovine serum and the suspensions centrifuged. The supernatant was aspirated and the cell pellet resuspended and stained. Polychromatic erythrocytes were scored for micronucleated polychromatic and normochromatic erythrocytes. Thalidomide did not increase revertant frequencies in all bacterial strains. It also did not produce any significant increase in the average mutant frequencies of AS52 cells and mouse micronucleated polychromatic erythrocytes. We conclude that Celgene's Thalomid thalidomide is non-genotoxic.
Similar articles
-
Genotoxicity evaluation of Hwanglyeonhaedok-tang, an herbal formula.J Ethnopharmacol. 2017 Apr 18;202:122-126. doi: 10.1016/j.jep.2016.11.051. Epub 2016 Dec 1. J Ethnopharmacol. 2017. PMID: 27916588
-
Genotoxicity studies on HM10760A, recombinant human erythropoietin conjugated to globin fragment.Drug Chem Toxicol. 2010 Apr;33(2):152-9. doi: 10.1080/01480540903196824. Drug Chem Toxicol. 2010. PMID: 19761439
-
Genotoxicity tests with 6-acetyl-1,1,2,4,4,7-hexamethyltetraline and 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylcyclopenta-gamma-2-benzopyr an.Mutat Res. 1999 Oct 29;446(1):67-81. doi: 10.1016/s1383-5718(99)00150-3. Mutat Res. 1999. PMID: 10613187
-
Mutagenicity and genotoxicity studies of aspartame.Regul Toxicol Pharmacol. 2019 Apr;103:345-351. doi: 10.1016/j.yrtph.2018.01.023. Epub 2018 Feb 19. Regul Toxicol Pharmacol. 2019. PMID: 29408486 Review.
-
Revisiting the bacterial mutagenicity assays: Report by a workgroup of the International Workshops on Genotoxicity Testing (IWGT).Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503137. doi: 10.1016/j.mrgentox.2020.503137. Epub 2020 Jan 13. Mutat Res Genet Toxicol Environ Mutagen. 2020. PMID: 32087853
Cited by
-
Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice.J Biomed Biotechnol. 2002;2(1):7-13. doi: 10.1155/S1110724302000359. J Biomed Biotechnol. 2002. PMID: 12488594 Free PMC article.
-
Anti-Hyperuricemic, Anti-Arthritic, Hemolytic Activity and Therapeutic Safety of Glycoconjugated Triazole-Phthalimides.Biomedicines. 2023 Sep 14;11(9):2537. doi: 10.3390/biomedicines11092537. Biomedicines. 2023. PMID: 37760978 Free PMC article.
-
The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage.Chem Res Toxicol. 2017 Aug 21;30(8):1622-1628. doi: 10.1021/acs.chemrestox.7b00127. Epub 2017 Aug 2. Chem Res Toxicol. 2017. PMID: 28745489 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous